Arctiin
CAS 20362-31-6
Arctiin (CAS 20362-31-6) is a pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 41500 nM | 4 | - |
| - | MIC | 50000 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Arctiin used for in pharmaceutical contexts?
Arctiin (CAS 20362-31-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Arctiin?
No adverse-event association or SIDER side-effect rows are rendered for Arctiin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Arctiin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Arctiin with EU status "permitted".
What clinical phase is Arctiin in?
No phase 1-4 clinical development badge is rendered for Arctiin because the matched compound identifier rows do not contain a max-phase value.